MK0966, rofecoxib + Comparator: valdecoxib
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Postoperative Pain
Conditions
Postoperative Pain
Trial Timeline
May 1, 2002 → —
NCT ID
NCT00092300About MK0966, rofecoxib + Comparator: valdecoxib
MK0966, rofecoxib + Comparator: valdecoxib is a phase 3 stage product being developed by Merck for Postoperative Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT00092300. Target conditions include Postoperative Pain.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00092300 | Phase 3 | Completed |
Competing Products
20 competing products in Postoperative Pain